Cellectis (CLLS) to Release Quarterly Earnings on Wednesday

Cellectis (NASDAQ:CLLS) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $10.74 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:00 AM ET.

Cellectis Trading Down 2.7%

Shares of CLLS stock opened at $3.56 on Monday. Cellectis has a 1-year low of $1.10 and a 1-year high of $5.48. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.63. The stock’s fifty day simple moving average is $4.07 and its 200-day simple moving average is $3.88.

Institutional Investors Weigh In On Cellectis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Global Retirement Partners LLC bought a new position in Cellectis during the fourth quarter worth $34,000. Acadian Asset Management LLC boosted its holdings in Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares during the period. Virtu Financial LLC acquired a new stake in Cellectis in the 3rd quarter worth $72,000. Millennium Management LLC increased its holdings in shares of Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares during the period. Finally, Citadel Advisors LLC bought a new position in shares of Cellectis during the 3rd quarter worth about $633,000. 63.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, January 21st. Jefferies Financial Group initiated coverage on shares of Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price target on the stock. Finally, Clear Str raised shares of Cellectis to a “strong-buy” rating in a research note on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cellectis has an average rating of “Moderate Buy” and a consensus target price of $6.33.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.